Washington, DC – This week, the House Agriculture Committee approved its version of the Farm Bill, moving the legislation to the floor for consideration...
Read More »
Benjamin Brewster, Chairman of the Board of Trustees of the Trudeau Institute, announced the appointment of Dr. Ronald H. Goldfarb as Trudeau’s sixth President, Director and CEO, effective October 1, 2012.
Dr. Goldfarb, who has more than 30 years of experience in cancer research and development in both academic and industrial settings, most recently served as President, CEO and Chief Scientific Officer of Sopherion Therapeutics, a privately-held biopharmaceutical company headquartered in Princeton,New Jersey, which he co-founded in 2002.
Prior to launching Sopherion, Dr. Goldfarb held a number of senior management positions heading large and complex programs in cancer research and drug development, including: Director of the Institute for Cancer Research at the University of North Texas Health Science Center; Deputy Director of the University of Pittsburgh Cancer Institute; and managing Cancer Research and Drug Discovery in the Department of Immunology & Infectious Disease for Pfizer Inc. Dr. Goldfarb has chaired multiple federal and state oncology peer-review panels/study sections for the National Cancer Institute, the American Cancer Society, the Veterans Affairs Administration, the U.S. Department of Defense, and the University of California.
He has also served as a member of the Veterans Affairs Merit Review Council, as well as on the scientific advisory boards of five biotechnology companies, including three of which he served as chairman.
Dr. Goldfarb also has held faculty appointments at the University of North Texas Health Science Center as Professor and Chairman of the Department of Molecular Biology & Immunology and the University of Pittsburgh School of Medicine as Professor of Pathology.
He is the holder ofU.S.and international patents in anti-cancer drug discovery and was awarded for Outstanding Service to the Cause of Cancer Control from the American Cancer Society in 2002.
The Trudeau Institute is a nonprofit biomedical research center founded in 1884 by Dr. E.L. Trudeau. The Institute’s fundamental research on immunity fosters the development of vaccines, treatments and cures for many life-threatening diseases, including cancer, tuberculosis and influenza. The Institute is supported by federal and state grants and contributions from individuals, private foundations and corporations. For further information about the Trudeau Institute, go to www.trudeauinstitute.org.